DNA vs. MESO, IDYA, AGIO, APGE, TARS, IOVA, AMPH, IRON, BLTE, and IBRX
Should you be buying Ginkgo Bioworks stock or one of its competitors? The main competitors of Ginkgo Bioworks include Mesoblast (MESO), IDEAYA Biosciences (IDYA), Agios Pharmaceuticals (AGIO), Apogee Therapeutics (APGE), Tarsus Pharmaceuticals (TARS), Iovance Biotherapeutics (IOVA), Amphastar Pharmaceuticals (AMPH), Disc Medicine (IRON), Belite Bio (BLTE), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.
Ginkgo Bioworks vs.
Mesoblast (NASDAQ:MESO) and Ginkgo Bioworks (NYSE:DNA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, community ranking, profitability, earnings and risk.
Mesoblast has a beta of 3.36, indicating that its share price is 236% more volatile than the S&P 500. Comparatively, Ginkgo Bioworks has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500.
Mesoblast has higher earnings, but lower revenue than Ginkgo Bioworks.
Mesoblast received 386 more outperform votes than Ginkgo Bioworks when rated by MarketBeat users. Likewise, 70.21% of users gave Mesoblast an outperform vote while only 46.15% of users gave Ginkgo Bioworks an outperform vote.
In the previous week, Mesoblast had 1 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 5 mentions for Mesoblast and 4 mentions for Ginkgo Bioworks. Mesoblast's average media sentiment score of 0.54 beat Ginkgo Bioworks' score of 0.44 indicating that Mesoblast is being referred to more favorably in the media.
Mesoblast presently has a consensus target price of $13.50, suggesting a potential downside of 21.97%. Ginkgo Bioworks has a consensus target price of $4.58, suggesting a potential downside of 57.70%. Given Mesoblast's stronger consensus rating and higher probable upside, analysts plainly believe Mesoblast is more favorable than Ginkgo Bioworks.
Mesoblast has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -298.78%. Mesoblast's return on equity of 0.00% beat Ginkgo Bioworks' return on equity.
1.4% of Mesoblast shares are owned by institutional investors. Comparatively, 78.6% of Ginkgo Bioworks shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by insiders. Comparatively, 9.7% of Ginkgo Bioworks shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Mesoblast beats Ginkgo Bioworks on 14 of the 16 factors compared between the two stocks.
Get Ginkgo Bioworks News Delivered to You Automatically
Sign up to receive the latest news and ratings for DNA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ginkgo Bioworks Competitors List
Related Companies and Tools
This page (NYSE:DNA) was last updated on 1/21/2025 by MarketBeat.com Staff
Free DNA Stock Alerts